Mitochonic Acid 5 Binds Mitochondria and Ameliorates Renal Tubular and Cardiac Myocyte Damage

Area of Science:

• Biochemistry
• Mitochondrial Biology
• Nephrology

Background:

• Mitochondrial dysfunction, characterized by increased oxidative stress and ATP depletion, contributes to renal diseases like chronic kidney disease (CKD) and acute kidney injury (AKI).
• Current antioxidant therapies show uncertain clinical efficacy for these conditions.
• A novel indole derivative, mitochonic acid 5 (MA-5), was previously shown to increase ATP levels and fibroblast survival in mitochondrial disease patients.

Purpose of the Study:

• To elucidate the mechanism of action of MA-5.
• To evaluate the therapeutic potential of MA-5 in preclinical models of kidney injury and mitochondrial disease.

Main Methods:

• In vitro bioenergetic studies using cell cultures (Hep3B cells).
• In vivo studies using rodent models: ischemia-reperfusion injury, cisplatin-induced nephropathy, and a mitochondrial disease model (Mitomice).
• Assays included ATP level measurement, reactive oxygen species (ROS) detection, mitochondrial complex activity assessment, and mitofilin interaction studies.

Main Results:

• MA-5 enhanced ATP production and reduced mitochondrial ROS in vitro without affecting mitochondrial complexes I-IV activity.
• MA-5 improved renal function in ischemia-reperfusion and cisplatin-induced nephropathy models.
• MA-5 was found to target the mitochondrial protein mitofilin, amplifying its effect on ATP levels.
• In Mitomice, MA-5 improved cardiac and renal mitochondrial respiration and showed a trend towards prolonged survival.

Conclusions:

• MA-5 modulates mitochondrial ATP synthesis via mitofilin, independent of oxidative phosphorylation.
• MA-5 demonstrates therapeutic potential for cardiac and renal diseases linked to mitochondrial dysfunction.
• MA-5 represents a novel therapeutic strategy distinct from traditional antioxidant therapies.